Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Avidity NanoMedicines Expands Investor Syndicate

October 7, 2014 – 7:01 am | Edit Post

LA JOLLA, Calif., Oct. 7, 2014 /PRNewswire/ — Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech. Other investors in the financing include Brace Pharmaceuticals, Partner Fund Management, L.P. and existing investor Alethea Capital Management. Ben Auspitz from Fidelity Biosciences and Eran Nadav, Ph.D. from TPG Biotech will join Avidity’s board as observers. Proceeds from the financing will be used to advance new cancer therapies that utilize the company’s proprietary antibody-siRNA complex (ARC(TM)) platform.

FDA Grants Orphan Drug Designation To DNAtrix’s DNX-2401 For The Treatment Of Malignant Glioma

October 7, 2014 – 6:00 am | Edit Post

SAN DIEGO, Oct. 7, 2014 /PRNewswire/ — DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical need. Under the designation, companies are provided with development and commercial incentives for designated compounds. The company’s DNX-2401 program has already been granted fast track status.

What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure

October 7, 2014 – 12:00 am | Edit Post

Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people who got laid off (or choose not…
[[Click headline to continue reading.]]

Trovagene to Present at 13th Annual BIO Investor Forum

October 6, 2014 – 1:30 pm | Edit Post

SAN DIEGO, Oct. 6, 2014 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.

Algae’s promise rebounds after setbacks

October 6, 2014 – 11:01 am | Edit Post

Tantalizing visions of an algae-powered economy emerged from San Diego summit.

Carefusion to be acquired for $12.2 billion

October 6, 2014 – 9:30 am | Edit Post

The San Diego-based medical technology giant Carefusion Corporation is being acquired by New Jersey-based Becton, Dickinson and Company in a deal for $12.2 billion, the company announced Friday.

RCSB Protein Data Bank Launches Mobile Application

October 6, 2014 – 9:03 am | Edit Post

The RCSB Protein Data Bank (PDB), which recently archived its 100,000th molecule structure, has introduced a free mobile application device that enables users from the general public and expert researchers to quickly search and visualize the 3D shapes of proteins, nucleic acids, and molecular machines.

2014 Fishman Fund Awards announced

October 6, 2014 – 6:00 am | Edit Post

Three gifted and promising young postdoctoral researchers were presented the prestigious Fishman Fund Award at the annual ceremony on October 2.

2014 Fishman Fund Awards announced

October 6, 2014 – 6:00 am | Edit Post

Three gifted and promising young postdoctoral researchers were presented the prestigious Fishman Fund Award at the annual ceremony on October 2.

2014 Fishman Fund Awards announced

October 6, 2014 – 6:00 am | Edit Post

Three gifted and promising young postdoctoral researchers were presented the prestigious Fishman Fund Award at the annual ceremony on October 2.